Search Medical Condition
Please enter condition
Please choose location

Montpellier Cedex 5, France Clinical Trials

A listing of Montpellier Cedex 5, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (135) clinical trials

Surgery in Treating Patients With Neuroblastoma

OBJECTIVES: - Evaluate the safety and efficacy of surgical treatment alone for stage II neuroblastoma without N-myc amplification (NMA). - Describe predictive factors of relapse and survival for stages I and II neuroblastoma without NMA treated by surgery alone. OUTLINE: Patients with localized resectable tumors undergo surgery. Postoperative evaluations are ...

Phase

0.0 miles

Learn More »

Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

OBJECTIVES: - Determine the 18-month survival rate of patients with metastatic renal cell carcinoma treated with allogeneic stem cell transplantation. - Determine the objective rate of response of patients treated with this regimen. - Determine post-transplant immunological reactions and recuperation of patients treated with this regimen. - Determine the antitumoral ...

Phase

0.0 miles

Learn More »

Intraoperative Radiotherapy After Local Recurrence in Breast Cancer

Currently, the rate of ipsilateral breast tumor recurrence (IBTR) after breast- conserving surgery and radiotherapy remains at 10% at 10 years to 15% at 20 years, respectively. IBTR is an independent predictor of poor survival with a 3 to 4.6 increased risk of cancer-related death. In a heterogeneous population, local ...

Phase

0.0 miles

Learn More »

Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

Regorafenib (BAY 73-4506) was assessed in metastatic colorectal cancer in the phase III randomized CORRECT trial. 760 metastatic colorectal cancer patients were recruited after the failure of all standard therapies. Given the promising efficacy and favorable tolerability profile of mGEMOX and the potential benefits of targeting the VEGF and Ras/Raf ...

Phase

0.0 miles

Learn More »

A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan

Given the therapeutic potential and reduced toxicity advantages of S-1 compared with other fluoropyrimidines, this trial assessing S-1 with Oxaliplatin plus Irinotecan is warranted for future investigations (Phase II-III). The primary objectives are to determine the Maximal Tolerated Dose (MTD), the Dose Limitant Toxicities (DLTs) and the safety profile of ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Primary objective of the study is to compare the efficacy of romidepsin when administered with CHOP versus CHOP alone in subjects with previously untreated peripheral T-cell lymphoma (PTCL) in terms of progression-free survival (PFS) assessed according to Response criteria for malignant lymphoma 1999 by RAC.

Phase

0.0 miles

Learn More »

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Not randomized, multicentric, national phase II trial estimating the efficacy of an intensification protocol in patients with refractory germ cell tumors with relapse and bad prognosis. Treatment consists in two Paclitaxel and Ifosfamide intensification cycles followed by three Carboplatine and Etoposide high dose cycles. The point is the individual Carboplatine ...

Phase

0.0 miles

Learn More »

Breast-Conserving Surgery Techniques in Treating Women With Breast Cancer

OBJECTIVES: Primary - Evaluate the percentage of histologically healthy margins maintained during resection in women with breast cancer. Secondary - Evaluate local recurrence at 5 years. - Evaluate aesthetic results. - Evaluate quality of life using the QLQC30 and BR23 questionnaires. OUTLINE: This is a multicenter study. Patients undergo oncoplastic ...

Phase

0.0 miles

Learn More »

Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma

Soft tissue sarcomas represent less than 1% of malignant tumors in adults and sarcomas members represent 60% of them. These rare tumors involve complex multidisciplinary care better in centers having expertise. Loco-regional therapy strategies have evaluated over time for tumors of members leading to propose more often the combination of ...

Phase

0.0 miles

Learn More »

Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors

OBJECTIVES: Primary - Identify factors predictive of treatment failure in patients with solid tumors treated with epoetin beta while undergoing chemotherapy. Secondary - Evaluate the impact of achieving target hemoglobin levels (i.e., hemoglobin > 11 g/dL) after 8 weeks of treatment with epoetin beta. - Evaluate changes in hemoglobin levels ...

Phase N/A

0.0 miles

Learn More »